Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

AtriCure Q3 Beat Triggers Higher 2026 Guidance and Target Raises

Nov 4, 2026, 6:23 AM EST1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Strong Q3 beat and raised 2026 guidance generally support a valuation upgrade; despite a small pre-market dip, similar past moves show stocks often rally after solid earnings and guidance raises when execution is credible.

AI summary

What happened, with direct paths to the underlying reporting

AtriCure posted a solid Q3 with earnings of $0.17 per share on revenue of $154.45 million, topping estimates. The company lifted its FY2026 adj EPS guidance to 40-46 cents and sales to $606-610 million, signaling stronger profitability. Progress on the BoxX-NoAF trial supports upside optionality, with analysts upshifting price targets to $70, though the stock traded slightly lower pre-market.

ATRC Q3: EPS 0.17 vs -0.05 expected; Revenue 154.45M vs 151.22M.
Guidance raised: FY2026 adj EPS 0.40-0.46; sales 606-610M.
BoxX-NoAF trial progress reinforces growth opportunities.
Shares fell 2% pre-market to $59.20.
BTIG and Needham raise PT to $70; both maintain Buy.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

AtriCure Q3 Beat Triggers Higher 2026 Guidance and Target Raises

AtriCure (ATRC) Gains China Approval for AtriClip LAA System